These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35109968)

  • 1. Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Sandmann FG; van Leeuwen E; Bernard-Stoecklin S; Casado I; Castilla J; Domegan L; Gherasim A; Hooiveld M; Kislaya I; Larrauri A; Levy-Bruhl D; Machado A; Marques DFP; Martínez-Baz I; Mazagatos C; McMenamin J; Meijer A; Murray JLK; Nunes B; O'Donnell J; Reynolds A; Thorrington D; Pebody R; Baguelin M
    Vaccine; 2022 Feb; 40(9):1306-1315. PubMed ID: 35109968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands.
    de Boer PT; Nagy L; Dolk FCK; Wilschut JC; Pitman R; Postma MJ
    Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
    Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
    BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany.
    Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    BMC Med; 2017 Sep; 15(1):166. PubMed ID: 28882149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives.
    de Fougerolles TR; Baïssas T; Perquier G; Vitoux O; Crépey P; Bartelt-Hofer J; Bricout H; Petitjean A
    BMC Public Health; 2024 May; 24(1):1222. PubMed ID: 38702667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes.
    de Boer PT; Backer JA; van Hoek AJ; Wallinga J
    BMC Med; 2020 Jan; 18(1):11. PubMed ID: 31931789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimising age coverage of seasonal influenza vaccination in England: A mathematical and health economic evaluation.
    Hill EM; Petrou S; Forster H; de Lusignan S; Yonova I; Keeling MJ
    PLoS Comput Biol; 2020 Oct; 16(10):e1008278. PubMed ID: 33021983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
    Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G
    Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study.
    Baguelin M; Camacho A; Flasche S; Edmunds WJ
    BMC Med; 2015 Oct; 13():236. PubMed ID: 26459265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis.
    Hodgson D; Baguelin M; van Leeuwen E; Panovska-Griffiths J; Ramsay M; Pebody R; Atkins KE
    Lancet Public Health; 2017 Feb; 2(2):e74-e81. PubMed ID: 28299371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential health and economic impact of paediatric vaccination using next-generation influenza vaccines in Kenya: a modelling study.
    Waterlow NR; Radhakrishnan S; Dawa J; van Leeuwen E; Procter SR; Lambach P; Bresee J; Mazur M; Eggo RM; Jit M
    BMC Med; 2023 Mar; 21(1):106. PubMed ID: 36949456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
    Van Bellinghen LA; Marijam A; Tannus Branco de Araujo G; Gomez J; Van Vlaenderen I
    Braz J Infect Dis; 2018; 22(1):1-10. PubMed ID: 29352897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccinating children against influenza increases variability in epidemic size.
    Backer JA; van Boven M; van der Hoek W; Wallinga J
    Epidemics; 2019 Mar; 26():95-103. PubMed ID: 30529023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.